Project Grant R44HL182393
Award Date 9/15/25
Completion Date 9/11/26
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Mattawan, MI, USA
Similar Awards
- This $1,488,899 Project Grant award was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a pharmaceutical research and development company based in Pennsylvania. The funding supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and cardiac function following myocardial infarction. The research aims to...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This Project Grant award of $1,290,338 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research conducted by Jaan Biotherapeutics, Inc. to develop a gene therapy treatment for heart muscle regeneration after myocardial infarction. The research aims to inhibit four specific microRNAs that regulate cardiomyocyte dedifferentiation, proliferation, and redifferentiation, with the goal of stimulating endogenous heart muscle regeneration and...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This Project Grant award from the National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), will fund the development of an optimized strategy to interrupt progressive ventricular wall remodeling associated with ischemic cardiomyopathy. The $695,865 award will support two key aims: 1) evaluating the functional, geometric, and histopathologic effects of three different thermoresponsive hydrogel formulations when injected into a porcine ischemic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. Specifically, the project aims to improve the efficacy of in-situ reprogramming of scar fibroblasts into cardiomyocytes through three key objectives: Investigating the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- This Project Grant award, in the amount of $746,800.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at Baylor College of Medicine to investigate the major signaling mechanism controlling spontaneous cardiomyocyte (heart cell) proliferation in the neonatal stage. The research aims to elucidate the role of the CD36 receptor in regulating heart cell regeneration, with a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...